Results 1 to 10 of about 51,359 (234)
Pioglitazone: Indian perspective
Indian Journal of Endocrinology and Metabolism, 2011 Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance.
Rishi Shukla, Sanjay Kalra
doaj +2 more sources
The efficacy of pioglitazone for renal protection in diabetic kidney disease.
PLoS ONE, 2022 There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients.
Chao-Chung Ho +5 more
doaj +2 more sources
Vnitřní lékařství, 2020 Pioglitazone belongs to the drugs primarily reducing insulin resistance. Currently, it is the only insulin sensitizer available. In addition to hypoglycaemic action, it has a number of other metabolically beneficial effects that are responsible for its positive effect on the vascular wall.
+7 more sources
International Journal of Clinical Practice, 2000 SUMMARYPioglitazone is a thiazolidinedione. As a PPAR‐γ agonist it alters the expression of a number of genes, resulting in a reduction in insulin resistance. Clinical trial data involving over 4500 patients with type 2 diabetes suggest it is effective both as monotherapy and in combination with sulphonylureas, metformin and insulin, producing both ...
J M, Lawrence, J P, Reckless
+7 more sources
Molecules, 2023 Pioglitazone, a PPAR-gamma activator used to diagnose hyperglycemia, was studied for its stereoselective deposition and active enantiomers in female albino Wistar rats.
Tatineni Spandana +8 more
doaj +1 more source
Hepatology Communications, 2021 The antidiabetic drug pioglitazone is, to date, the most efficacious oral drug recommended off‐label for the treatment of nondiabetic or diabetic patients with biopsy‐proven nonalcoholic steatohepatitis (NASH). However, weight gain and edema side effects
Vincent Jacques +8 more
doaj +1 more source
Pioglitazone - the forgotten drug with multidirectional action
Journal of Education, Health and Sport, 2023 Introduction: Pioglitazone (PG) which belongs to thiazolidinedione class is a drug used in the treatment of type 2 diabetes. PG increases the insulin sensitivity of peripheral tissues.
Arkadiusz Aab, Julia Zarańska
doaj +1 more source
Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects [PDF]
International Neurourology Journal, 2020 Purpose Pioglitazone, an antihyperglycemic drug, is widely used in diabetes mellitus patients with insulin resistance. Although pioglitazone is known to have a potential link to bladder cancer (BC), there have been contradictory results.
Muhammad Shahid +6 more
doaj +1 more source
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial. [PDF]
PLoS ONE, 2018 BACKGROUND:Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects.
Bancha Satirapoj +2 more
doaj +1 more source
Pioglitazone abrogates testicular damage induced by testicular torsion/detorsion in rats [PDF]
Iranian Journal of Basic Medical Sciences, 2019 Objective(s): Testicular torsion/detorsion (T/D) is a well-known cause for infertility. Pioglitazone is an agonist of peroxisome proliferator activated receptor-gamma (PPAR-γ).
Nevertyty Mohamed Mahmoud +1 more
doaj +1 more source